Bristol-Myers Squibb Pharmaceutical Research and Development, Princeton, NJ 08543, USA.
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1436-9. doi: 10.1016/j.bmcl.2009.12.085. Epub 2010 Jan 4.
Design and synthesis of pyrazolodihydropyrimidines as KV1.5 blockers led to the discovery of 7d as a potent and selective antagonist. This compound showed atrial selective prolongation of effective refractory period in rabbits and was selected for clinical development.
设计并合成了作为 Kv1.5 阻断剂的吡唑并[1,5-a]嘧啶二氢嘧啶,从而发现了 7d 是一种有效且选择性的拮抗剂。该化合物在兔子中显示出心房选择性的有效不应期延长,并被选为临床开发。